.svg "close (3)"){kind=small}
Image Source: Adobe Stock
Morning Research Notes - 14.02.25
US markets closed higher on Thursday, buoyed by President Donald Trump’s decision to delay the implementation of reciprocal tariffs on U.S. trading partners, providing a window for potential negotiations. Commodities also closed mixed: Gold remained flat at $US2,897.82 an ounce, Brent oil fell by 2.4% to $US75.15 a barrel, and Iron ore increased by 1.8% to $US107.80 a tonne.
Wall Street closed higher last night after President Trump signed an executive order to explore reciprocal tariffs on U.S. trading partners, but stopped short of implementing them immediately. The Dow Jones Industrial Average rose 342 points (0.8%), the S&P 500 climbed 1%, and the Nasdaq increased by 1.5%. Nvidia led tech stocks higher, gaining over 3% after Hewlett Packard Enterprise shipped its first Nvidia AI computing Blackwell system. However, more hot inflationary data was released, with the U.S. producer price index rising 0.4% in January, exceeding expectations.
The Australian stock market closed higher on Wednesday, with the ASX 200 rising by 0.05%. The Materials sector performed well, gaining 1.52%. In contrast, Financials (-0.30%), Information Technology (-0.21%), Utilities (-2.36%), and Healthcare (-0.66%) ended the day in the red. The commodities sector saw strong performance, with Copper, Zinc, and Nickel closing higher by 0.35%, 1.88%, and 0.16% respectively. However, Aluminium fell by 0.7%.
Chart of the day
Life science organisations are expected to increase their gen AI budgets. According to a McKinsey survey of pharma and MedTech leaders, the share of companies spending $5 million or more on gen AI is expected to grow from 20 percent in 2024 to 32 percent in 2025. The proportion of organisations spending less than $5 million is expected to decrease from 70 percent in 2024 to 56 percent in 2025.
Source: McKinsey
If you want to receive our top 3 income stocks click on the button below:
Invest Well,
Australian Stock Report
This report has been prepared by Atlantic Pacific Securities Pty Limited trading as ASR Wealth Advisers ABN 72 135 187 085 (“ASRW”) CAR 339207 of Amalgamated Australian Investment Solutions Pty Ltd (AAIS) (AFSL 314 614 - ABN: 61 123 680 106) and distributed with its consent by Australian Stock Report Pty Ltd ABN 94 106 863 978 (ASR) AFSL 301682. ASRW and ASR are part of Amalgamated Australian Investment Group Limited ABN 81 140 208 288. Whilst the information presented herein is believed to be reliable and sourced from public sources thought to be reliable, neither ASRW nor ASR make any representations as to its accuracy or completeness. This report is provided for informational purposes only. It is not an offer or a solicitation of an offer to buy or sell any financial products or to participate in any particular trading strategy. Any advice perceived to be included within this report is provided on a general advice basis only and therefore it does not take into account personal financial situation, objectives and needs of any individual. Before making any decision about financial products, investors must consider whether it is appropriate for them in light of their personal circumstances and seek professional investment, tax, legal and/or personal financial advice. Where applicable, investors should obtain and consider a Product Disclosure Statement, prospectus or other disclosure material relevant to the financial product before making a decision to acquire it.
ASRW’s, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Opinions, estimates and projections constitute the current judgement of the author as at the date of this report. They do not necessarily reflect the opinions of ASRW or any of their related entities, must not be seen as an endorsement in any way and are subject to change without notice. ASRW has no obligation to update, modify or amend this report or otherwise notify a recipient if any opinion, forecast or estimate contained herein changes or subsequently becomes inaccurate. Target prices are inherently imprecise and a product of the analyst’s judgement. Prices and availability of financial products are subject to change without notice and investment transactions can lead to losses as a result of price fluctuations, extreme volatility and other factors. If a financial product is denominated in a currency other than an investor’s currency, a change in exchange rates may adversely affect the investment.
Investing in financial markets involves risk and investments may go up and down. The payment of income and the return of capital are not guaranteed. Past performance is not an indicator of future results. Macroeconomic fluctuations often account for most of the risks associated with exposures to instruments that offer fixed or variable interest rates. Upside surprises in inflation, fiscal funding needs, and FX depreciation rates are among the most common adverse macroeconomic shocks that may impact the market value of any investment. Counterparty exposure, issuer creditworthiness, client segmentation, regulation, changes in tax policies, currency convertibility and settlement issues related to local clearing houses are also important risk factors to take into consideration.
The opinions and recommendations in the research report are based on a reasonable assessment by the research staff member who wrote the report using information provided by the product issuer and generally available in the market. ASRW’s research staff are well qualified and give their opinions and recommendations on reasonable grounds and based on the information available to them. ASRW’s research staff are remunerated by salary and do not receive any commissions or fees. Annual bonuses may be paid on a discretionary basis and as relevant to their role. Employees and/or associates of ASRW, ASR and their related entities may hold one or more of the stocks, securities or investments reviewed in this report. Any personal holdings by employees and/or associates of ASRW, ASR and their related entities should not be seen as an endorsement or recommendation in any way. For information about ASRW, its financial services and Financial Services Guide, please visit www.asrw.com.au .
